Patents by Inventor Gary A. Cain

Gary A. Cain has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6417394
    Abstract: This invention pertains to novel salt forms of trophenylethylene compound, such as 3-[4(1,2-diphenyl-but-1-enyl)-phenyl]-acrylic acid, as selective estrogen receptor modulators. This invention also provides methods for the treatment and/or prevention of breast, uterine, ovarian, prostrate and colon cancer, osteoporosis, cardiovascular disease, and benign proliferative disorders, as well as pharmaceutical compositions of the compounds of the present invention.
    Type: Grant
    Filed: April 3, 2001
    Date of Patent: July 9, 2002
    Assignee: Bristol Myers Squibb Pharma Company
    Inventors: Gary A. Cain, Reginald O. Cann, Christopher A. Teleha, Denette K. Murphy
  • Publication number: 20020004496
    Abstract: This invention pertains to novel salt forms of trophenylethylene compound, such as 3-[4(1,2-diphenyl-but-1-enyl)-phenyl]-acrylic acid, as selective estrogen receptor modulators. This invention also provides methods for the treatment and/or prevention of breast, uterine, ovarian, prostrate and colon cancer, osteoporosis, cardiovascular disease, and benign proliferative disorders, as well as pharmaceutical compositions of the compounds of the present invention.
    Type: Application
    Filed: April 3, 2001
    Publication date: January 10, 2002
    Inventors: Gary A. Cain, Reginald O. Cann, Christopher A. Teleha, Denette K. Murphy
  • Publication number: 20010041714
    Abstract: The present invention relates to compounds having pharmacological activity toward the 5-HT7 receptor. Pharmaceutical compositions and methods for their use in the treatment of CNS disorders are described.
    Type: Application
    Filed: March 7, 2001
    Publication date: November 15, 2001
    Inventors: Gary A. Cain, John F. McElroy
  • Patent number: 6166211
    Abstract: The present invention pertains to a process for the preparation of the 10-keto analogs of morphinan compounds. In the case of compounds having a 3-hydroxyl group, the 3-methyl ether protected analog is synthesized by selective phenolic methylation in the presence of the basic amino group. When nalbuphine, morphine, or codeine is used as the starting material, the additional 6-hydroxyl group is protected using acetylation. The protected analog is selectively oxidized by treatment with cerium ammonium nitrate to provide the 10-(S)-hydroxy adduct. The 10-(S)-hydroxy adduct is further oxidized to the 10-keto analog. Any protecting groups that were added prior to oxidation are cleaved subsequent to oxidation to form the desired 10-ketomorphinan.
    Type: Grant
    Filed: March 7, 2000
    Date of Patent: December 26, 2000
    Assignee: Endo Pharmaceuticals, Inc.
    Inventors: Gary A. Cain, Spencer Drummond, Jr.
  • Patent number: 5523302
    Abstract: This invention relates to novel compounds containing basic and acidic termini, pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of platelet aggregation, as thrombolytics, and/or for the treatment of thromboembolic disorders.
    Type: Grant
    Filed: November 24, 1993
    Date of Patent: June 4, 1996
    Assignee: The Du Pont Merck Pharmaceutical Company
    Inventors: Gary A. Cain, Charles J. Eyermann
  • Patent number: 5317024
    Abstract: Novel unsaturated ether derivatives of alkyl piperidine and pyrrolidine compounds, pharmaceutical compositions containing them, methods of preparation and methods of using these compounds as antipsychotic agents are disclosed.
    Type: Grant
    Filed: August 3, 1993
    Date of Patent: May 31, 1994
    Assignee: DuPont Merck Pharmaceutical Co.
    Inventors: Gary A. Cain, Thomas E. Christos, Sang W. Tam
  • Patent number: 5296479
    Abstract: There are provided cycloalkyl piperidine compounds which are useful in the treatment of physiological or drug-induced psychosis or dyskinesia in a mammal. These novel compounds are selective sigma receptor antagonists and have a low potential for movement disorder side effects associated with typical antipsychotic agents.
    Type: Grant
    Filed: February 6, 1992
    Date of Patent: March 22, 1994
    Assignee: The Du Pont Merck Pharmaceutical Company
    Inventors: Gary A. Cain, Paul J. Gilligan, Sang W. Tam
  • Patent number: 5266572
    Abstract: There are provided cycloalkyl piperidine compounds which are useful in the treatment of physiological or drug-induced psychosis or dyskinesia in a mammal. These novel compounds are selective sigma receptor antagonists and have a low potential for movement disorder side effects associated with typical antipsychotic agents.
    Type: Grant
    Filed: June 18, 1992
    Date of Patent: November 30, 1993
    Assignee: The Du Pont Merck Pharmaceutical Company
    Inventors: Gary A. Cain, Paul J. Gilligan, Sang W. Tam
  • Patent number: 5252586
    Abstract: Novel unsaturated ether derivatives of alkyl piperidine and pyrrolidine compounds, pharmaceutical compositions containing them, methods of preparation and methods of using these compounds as antipsychotic agents are disclosed.
    Type: Grant
    Filed: September 28, 1990
    Date of Patent: October 12, 1993
    Assignee: The Du Pont Merck Pharmaceutical Company
    Inventors: Gary A. Cain, Thomas E. Christos, Sang W. Tam
  • Patent number: 5243048
    Abstract: There are provided cycloalkyl piperidine compounds which are useful in the treatment of physiological or drug-induced psychosis or dyskinesia in a mammal. These novel compounds are selective sigma receptor antagonists and have a low potential for movement disorder side effects associated with typical antipsychotic agents.
    Type: Grant
    Filed: February 6, 1992
    Date of Patent: September 7, 1993
    Assignee: The Du Pont Merck Pharmaceutical Company
    Inventors: Gary A. Cain, Paul J. Gilligan, Sang W. Tam
  • Patent number: 5169855
    Abstract: There are provided piperidine ether derivatives, pharmaceutical and agricultural compositions containing them useful for treating physiological or drug induced psychosis or dyskinesia in a mammal or fungal disease in plants. Also provided are methods for preparing these compounds.
    Type: Grant
    Filed: March 28, 1990
    Date of Patent: December 8, 1992
    Assignee: Du Pont Merck Pharmaceutical Company
    Inventors: Gary A. Cain, Paul J. Gilligan, Sang W. Tam
  • Patent number: 5116846
    Abstract: There are provided N-aralkyl piperidine derivatives which are selective sigma receptor antagonists. These compounds and pharmaceutical compositions containing them are useful for treating physiological or drug induced psychosis or dyskinesia in a mammal.
    Type: Grant
    Filed: March 28, 1990
    Date of Patent: May 26, 1992
    Assignee: Du Pont Merck Pharmaceutical Company
    Inventors: Gary A. Cain, Paul J. Gilligan, Sang W. Tam
  • Patent number: 5109002
    Abstract: There are provided cycloalkyl piperidine compounds which are useful in the treatment of physiological or drug-induced psychosis or dyskinesia in a mammal. These novel compounds are selective sigma receptor antagonists and have a low potential for movement disorder side effects associated with typical antipsychotic agents.
    Type: Grant
    Filed: August 20, 1990
    Date of Patent: April 28, 1992
    Assignee: Du Pont Merck Pharmaceutical Company
    Inventors: Gary A. Cain, Paul J. Gilligan, Sang W. Tam